Rare Hematologic Disease Therapeutics Market

The Rare Hematologic Disease Therapeutics Market is led by Hospitals in the end user segment, with a 53.9% share in 2026. The therapy type segment is led by Gene Therapy at 40.6%, and the line of therapy segment by First-line at 40.0%.